CYP450 and drug efflux transporters polymorphism influence clinical outcomes of Thai osimertinib-treated non-small cell lung cancer patients

Background: Osimertinib has shown greater efficacy than standard epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and fewer grade 3 or higher adverse drug reactions (ADRs) in patients with advanced non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (...

Descripción completa

Detalles Bibliográficos
Autores principales: Majam, Teerapat, Sukasem, Chonlaphat, Reungwetwattana, Thanyanan, Chansriwong, Phichai, Atasilp, Chalirmporn, Trachu, Narumol, Thamrongjirapat, Thanaporn, Sukprasong, Rattanaporn, Meanwatthana, Jennis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10657898/
https://www.ncbi.nlm.nih.gov/pubmed/38026963
http://dx.doi.org/10.3389/fphar.2023.1222435

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10657898/
https://www.ncbi.nlm.nih.gov/pubmed/38026963
http://dx.doi.org/10.3389/fphar.2023.1222435

Ejemplares similares